Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 184,915 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NOT program Clear all
Active, not recruiting No phase listed Observational

A Longitudinal Study of COVID-19 Sequelae and Immunity

NCT04411147
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 31, 2026, 6:21 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Rural COPD E-Visit Study

NCT06236347
View directory record Official record
Conditions
Smoking Cessation
Interventions
Smoking cessation e-visit, Treatment as usual
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Kale Consumption on Human Xenobiotic Metabolizing Enzymes

NCT03449849
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Base Diet, Kale Treatment
Other
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
21 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 31, 2026, 6:21 PM EDT
Not listed No phase listed Observational

Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft

NCT02879149
View directory record Official record
Conditions
Ankle and Hindfoot Arthrodesis
Interventions
AUGMENT® Bone Graft, Standard of Care
Device · Procedure
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Tucson, Arizona • Capitola, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Phase 2 Interventional

An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee

NCT00211549
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
IDEA-033
Drug
Lead sponsor
IDEA AG
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
100
States / cities
Birmingham, Alabama • Montgomery, Alabama • Northport, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2009 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

NCT03976349
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIIB094, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Farmington Hills, Michigan • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Systematic Evaluation of Antiviral Medication in Schizophrenia

NCT00514449
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
Konasale Prasad
Other
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Detroit, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 31, 2026, 6:21 PM EDT
Terminated Phase 2 Interventional Results available

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

NCT04221438
View directory record Official record
Conditions
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
Interventions
Binimetinib, Conventional Surgery, Encorafenib, Fluorothymidine F-18
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Ann Arbor, Michigan • City of Saint Peters, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Phase 2 Interventional

Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor

NCT00006358
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 31, 2026, 6:21 PM EDT
Not listed No phase listed Observational

Discovering Clinical Study Experiences of Patients With Pulmonary Hypertension

NCT05918458
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

NCT03457948
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Interventions
Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate, Yttrium-90 Microsphere Radioembolization
Procedure · Biological · Device
Lead sponsor
Nicholas Fidelman, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine in Pathologic Skin Picking

NCT01063348
View directory record Official record
Conditions
Pathologic Skin Picking, Neurotic Excoriation, Psychogenic Excoriation, Dermatillomania
Interventions
N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 31, 2026, 6:21 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

DBS Recordings to Characterize Movement Facilitation in Parkinson's Disease

NCT05166655
View directory record Official record
Conditions
Parkinson Disease
Interventions
Movement task
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1020-CP-001

NCT03179878
View directory record Official record
Conditions
Healthy Volunteer, Urea Cycle Disorder
Interventions
Placebo, SYNB1020
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 31, 2026, 6:21 PM EDT
Not listed No phase listed Observational

Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism

NCT02361255
View directory record Official record
Conditions
Secondary Parkinsonism, Parkinson's Disease
Interventions
no intervention
Other
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
40 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Not applicable Interventional Results available

Ketone Supplementation in Cystic Fibrosis

NCT04938726
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ketone Monoester
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 31, 2026, 6:21 PM EDT
Active, not recruiting Not applicable Interventional

The REST Study for CGM Use in Older Adults With Insulin-treated Diabetes

NCT05337826
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitor
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
65 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 6:21 PM EDT
Active, not recruiting Not applicable Interventional

The Arteriovenous Vascular (AV) ACCESS Trial

NCT04646226
View directory record Official record
Conditions
End-Stage Kidney Disease, Hemodialysis Complication
Interventions
AV graft, surgical intervention for creation of a fistula
Device · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Not applicable Interventional

RENEW-AI: Personalizing Scleroderma Management With an AI Health Coach

NCT06999226
View directory record Official record
Conditions
Scleroderma
Interventions
RENEW-AI
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Not applicable Interventional

Droxidopa in Treating Patients With Neurogenic Hypotension

NCT00004478
View directory record Official record
Conditions
Shy-Drager Syndrome, Orthostatic Hypotension
Interventions
droxidopa
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Oct 31, 2026, 6:21 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia

NCT07082478
View directory record Official record
Conditions
Hypoglycemia, Cerebral Blood Flow
Interventions
in-ear device measuring blood flow
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 31, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

NCT01251978
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
Ranibizumab 2 mg, 0.5 mg Ranibizumab
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 31, 2026, 6:21 PM EDT
Terminated Phase 2 Interventional Results available

A Study of XmAb23104 in People With Sarcoma

NCT05879185
View directory record Official record
Conditions
Sarcoma
Interventions
XmAb23104
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 6:21 PM EDT